Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response

This publication has 63 references indexed in Scilit:

• MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to Sorafenib
  Journal of Biological Chemistry, 2009
• Causes and consequences of microRNA dysregulation in cancer
  Nature Reviews Genetics, 2009
• Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
  Science, 2009
• Sorafenib in Advanced Hepatocellular Carcinoma
  New England Journal of Medicine, 2008
• Intrahepatic Cholangiocarcinoma
  Annals of Surgery, 2008
• Prognostic molecular markers in hepatocellular carcinoma: A systematic review
  European Journal of Cancer, 2007
• A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular Carcinoma
  JNCI: Journal of the National Cancer Institute, 2005
• Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival
  Liver Transplantation, 2003
• p53 Status and the Efficacy of Cancer Therapy in Vivo
  Science, 1994
• Mutations in the p53 gene occur in diverse human tumour types
  Nature, 1989